Anavex Life Sciences (NASDAQ:AVXL) has received a No Objection Letter from Health Canada and Medicines and Healthcare products Regulatory Agency in the UK to expand the Phase 2b/3 study of ANAVEX2-73-AD-004 of ANAVEX 2-73 (blarcamesine) for the treatment of early Alzheimer’s disease (AD) into Canada and the UK, respectively.
The 48-week study using biomarker and precision
medicine in 450 patients with early AD is ongoing and currently over 50%
enrolled.
https://seekingalpha.com/news/3580384-anavex-on-go-to-expand-anavex-2minus-73-study-in-alzheimers
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.